What it's for (Indications)
- Calcipotriol is a synthetic vitamin D3 analog primarily indicated for the topical treatment of psoriasis vulgaris.
- Specifically, it is prescribed for the management of mild to moderate chronic plaque psoriasis in adults.
- It can be effectively used on various body areas, including the trunk, limbs, and scalp.
- Its action targets the hyperproliferation and abnormal differentiation of keratinocytes, which are characteristic hallmarks of psoriatic lesions.
- Calcipotriol offers a non-steroidal option for long-term management and can be used alone or in combination with other topical or systemic therapies, depending on the severity and extent of the condition.
- It is important to confirm the diagnosis of psoriasis vulgaris before initiating treatment with calcipotriol to ensure appropriate and effective therapy for the specific skin condition.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Calcipotriol is typically applied topically to affected skin areas once or twice daily, as directed by a healthcare professional. It is available in various formulations, including cream, ointment, and scalp solution, usually at a concentration of 50 micrograms/gram or 50 micrograms/mL. The medication should be applied as a thin layer to the psoriatic lesions only, and not to unaffected skin. To minimize the risk of systemic effects, particularly hypercalcemia, it is crucial not to exceed the maximum recommended weekly dose. For adults, the maximum weekly dose generally should not exceed 100 grams of calcipotriol 50 micrograms/gram ointment or cream. When used in combination products with corticosteroids (e.g., calcipotriol/betamethasone), specific weekly limits (e.g., 60 grams) apply. The treated area should generally not exceed 30% of the total body surface area. Patients must wash their hands thoroughly after applying the medication to prevent unintended transfer to other body parts, especially the face and eyes. Treatment duration is guided by clinical response and physician discretion, often involving long-term intermittent therapy. |
Safety & Warnings
Common Side Effects
- Common side effects associated with topical calcipotriol application are primarily localized and include skin irritation such as burning, itching, erythema (redness), dryness, peeling, and contact dermatitis.
- Less frequently, patients may experience worsening of psoriasis, photosensitivity, or skin atrophy if used on delicate skin areas for prolonged periods.
- Systemic side effects are rare when calcipotriol is used as directed, but can occur with excessive application, prolonged use, or application to extensive body surface areas.
- The most significant systemic side effect is hypercalcemia (elevated calcium levels in the blood) and hypercalciuria (elevated calcium in urine), which can manifest as nausea, vomiting, constipation, muscle weakness, and fatigue.
- Other potential, though rare, side effects include angioedema and facial edema.
- Ocular irritation can occur if the product inadvertently comes into contact with the eyes.
- Patients should be advised to report any persistent or severe adverse reactions to their healthcare provider.
Serious Warnings
- Black Box Warning: Calcipotriol, a synthetic vitamin D3 analog, does not carry an official FDA Black Box Warning. However, serious warnings regarding its use are imperative. The primary concern is the potential for systemic absorption leading to hypercalcemia, especially with excessive application, prolonged use, or application over large body surface areas. While generally reversible upon discontinuation or dose reduction, severe hypercalcemia can manifest with serious symptoms including polyuria, polydipsia, nausea, vomiting, constipation, muscle weakness, fatigue, and can lead to renal and cardiovascular complications. Patients must be counselled rigorously against exceeding recommended dosages and treatment durations. Close monitoring for signs and symptoms of hypercalcemia is crucial. The risk of hypercalcemia is heightened in patients with pre-existing disorders of calcium metabolism, severe renal impairment, or those receiving concomitant systemic vitamin D supplements or calcium. Additionally, calcipotriol may increase photosensitivity in some individuals, necessitating appropriate sun protection measures during treatment to mitigate the risk of severe sunburn and other photo-induced dermatological reactions.
- Calcipotriol is contraindicated in patients with known disorders of calcium metabolism, such as hypercalcemia or hypercalciuria, due to its potential to affect systemic calcium levels.
- It should not be used on the face, eyes, or mucous membranes due to the risk of irritation and absorption.
- Patients should be instructed to wash their hands immediately after application.
- Caution is advised when treating patients with severe renal or hepatic impairment, as their ability to metabolize and excrete calcipotriol may be compromised, increasing the risk of systemic exposure and hypercalcemia.
- Concomitant exposure to natural or artificial ultraviolet (UV) light should be monitored, as calcipotriol may cause photosensitivity and can be degraded by UV radiation.
- Pregnant or lactating women should use calcipotriol only if the potential benefit justifies the potential risk to the fetus or infant, as data on safety in these populations are limited.
- Calcipotriol is not recommended for use in erythrodermic, exfoliative, or pustular psoriasis due to a potential for increased systemic absorption and the severity of these conditions.
How it Works (Mechanism of Action)
Calcipotriol exerts its therapeutic effects by acting as a synthetic analog of calcitriol, the active form of vitamin D3. Its primary mechanism involves binding to the vitamin D receptor (VDR), which is widely expressed in various cells, including keratinocytes. In psoriasis, keratinocytes exhibit abnormally rapid proliferation and impaired differentiation. Upon binding to the VDR in keratinocytes, calcipotriol modulates gene transcription, leading to two key actions: it inhibits the excessive proliferation of keratinocytes and promotes their normal differentiation. This helps to normalize the cell growth and maturation process in psoriatic plaques. Additionally, calcipotriol possesses immunomodulatory properties, influencing the expression of various cytokines and chemokines that contribute to the inflammatory component of psoriasis. By reducing inflammation and regulating keratinocyte kinetics, calcipotriol effectively mitigates the characteristic skin lesions of psoriasis vulgaris. While its topical application minimizes systemic effects, high doses or extensive application can lead to systemic absorption and potential effects on calcium metabolism due to its vitamin D-like activity.